New Report Shows Plandai Biotechnology's Diabetes Research More Important Than Ever
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 11/19/13 -- Late last week the International Diabetes Federation (IDF) released a report filled with some staggering statistics in the fight against diabetes. Plandaí Biotechnology, Inc. (OTCQB: PLPL) feels it is producing products that can make a difference in the fight against the disease, and in light of these new numbers from the IDF, those products will be more welcomed than ever.
The company's Phytofare™ Catechin Complex is one of the candidates that Plandaí feels can make a difference in the ongoing battle to control diabetes. In the IDF's report it stated that worldwide 382 million people live with diabetes which is up from 285 million just four short years ago. According to the IDF, there are no signs of slowing as the number of people affected by the disease is expected to climb 55 percent to 592 million by 2035.
These dismal numbers don't include the many millions of undiagnosed cases around the world which is equally as troubling. Annual healthcare spending for diabetes is estimated to be $548 billion by the IDF, and as soon as 2018, the annual market for diabetes drugs and devices alone is projected to reach over $114 billion worldwide.
Factors such as poor diet, a more sedentary lifestyle, and increases in obesity and life expectancy are some of the reasons for the dramatic rise in newly diagnosed cases. David Whiting is an epidemiologist and public health specialist with the IDF, and he says, "Year after year, the figures seem to be getting worse. All around the world we are seeing increasing numbers of people developing diabetes."
Plandaí feels it can address some of these specific issues head on with its products. Green tea catechins (specifically EGCG) have been well documented to induce weight loss through a process called "thermogenesis" which essentially increases the metabolic rate allowing more fat to be burned.
Continue Reading: .
About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, Interviews and Feature Articles. For more information and to read disclaimers and disclosures:
Contact:
Stock Market Media Group
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.11.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 1284769
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Food
Anmerkungen:
Diese Pressemitteilung wurde bisher 90 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New Report Shows Plandai Biotechnology's Diabetes Research More Important Than Ever
"
steht unter der journalistisch-redaktionellen Verantwortung von
Plandai Biotechnology, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
